Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals has been acquired by Chiesi Group and is being taken private. Chiesi completed a tender offer for all KalVista common shares at $27.00 in cash per share, with approximately 43,152,532 shares, or 77.8% of outstanding shares, validly tendered.
After the tender offer, a short-form merger under Delaware law was completed, converting all remaining shares into the right to receive the same cash price and making KalVista a wholly owned Chiesi subsidiary. KalVista’s stock has ceased trading on the Nasdaq Global Market, and the company plans to deregister its shares and suspend SEC reporting.
The filing also details updated terms for KalVista’s 3.250% Convertible Senior Notes due 2031, which are now convertible into $1,606.28 in cash per $1,000 principal amount, executive transaction bonuses, a tax gross-up agreement for the CFO, termination of equity plans, and a full board change with Chiesi’s designee becoming sole director.
KalVista Pharmaceuticals director Nancy Stuart reported the disposition of stock options in connection with the company’s acquisition by Chiesi Farmaceutici. A Chiesi subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary.
Under the merger terms, each outstanding KalVista stock option with an exercise price below $27.00 became fully vested, was cancelled, and converted into a right to receive cash equal to the in-the-money value multiplied by the number of option shares. Any option with an exercise price at or above $27.00 was cancelled with no payment. After these transactions, the filing shows no remaining derivative positions for Stuart.
KalVista Pharmaceuticals director Brian JG Pereira reported the disposition of stock options in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, he surrendered multiple fully vested options covering a total of 91,000 shares of common stock to the issuer.
Under the Agreement and Plan of Merger, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Options with exercise prices below $27.00 were cancelled and converted into cash rights based on the spread between the merger price and each option’s exercise price, while any options with exercise prices equal to or above $27.00 were cancelled for no consideration.
KalVista Pharmaceuticals director William Fairey reported the disposition to the issuer of three stock option awards in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, options covering 30,000, 10,000, and 17,000 shares of common stock were cancelled, leaving no remaining options from these grants.
Under the Merger Agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Each in-the-money option automatically vested and was converted into a cash right based on the difference between the $27.00 Merger Consideration and the option’s exercise price, while any options with exercise prices at or above $27.00 were cancelled for no payment.
KalVista Pharmaceuticals, Inc. chief medical officer Paul K. Audhya reported the disposition of his equity awards in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici S.p.A. On June 11, 2026, his holdings in 150,260 shares of common stock were cancelled.
The filing shows additional dispositions of restricted stock units covering 93,750, 68,750, and 40,000 shares of common stock, as well as stock options over 25,800 shares at $9.28 and 100,000 shares at $24.97 per share. According to the merger agreement, in-the-money options and RSUs became fully vested and were converted into cash based on the $27.00 per-share merger consideration, while options with exercise prices at or above $27.00 were cancelled without payment. Following these transactions, the report shows no remaining holdings for the reporting person.
KalVista Pharmaceuticals director Bethany Sensenig reported the disposition of stock options as part of the company’s merger with Chiesi Farmaceutici. A total of 45,000 options with a per share exercise price of $12.05 were cancelled and converted into a cash right based on the merger consideration of $27.00 per share. Following the transaction, no options from this grant remain outstanding.
KalVista Pharmaceuticals director Patrick Treanor reported the disposition of several stock option grants to the issuer in connection with KalVista’s cash merger with Chiesi Farmaceutici. Under the merger, all KalVista common shares were acquired for $27.00 per share, and his fully vested in-the-money options were cancelled and converted into cash rights based on the spread between this merger price and each option’s exercise price.
KalVista Pharmaceuticals, Inc. Chief Commercial Officer Nicole Sweeny reported the disposition of her equity in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici. On June 11, 2026, she disposed of 59,291 shares of common stock and cancelled multiple restricted stock unit (RSU) awards and stock options back to the issuer.
Under the merger agreement, all outstanding KalVista common shares were acquired via a cash tender offer at $27.00 per share, and unexercised options and RSUs were cancelled in exchange for cash based on this consideration, or cancelled without payment if the option exercise price was at or above $27.00. Following these transactions, Sweeny reports zero shares and zero derivatives owned, reflecting the cash-out of her position as KalVista became a wholly owned subsidiary of Chiesi.
KalVista Pharmaceuticals' Chief Operations Officer, Arif Bilal, reported the cash-out of equity awards tied to the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, 49,000 restricted stock units and 100,000 stock options were disposed of to the issuer as part of a completed merger.
Under the Merger Agreement, Chiesi’s subsidiary acquired all outstanding KalVista common shares for $27.00 per share in cash, then merged with KalVista, which now operates as a wholly owned subsidiary. Unexercised options with an exercise price below the $27.00 merger consideration and outstanding RSUs were fully vested, cancelled, and converted into cash payments based on formulas set in the agreement, while underwater options were cancelled with no payment.
KalVista Pharmaceuticals director Reid Laurence reported the disposition of a stock option grant in connection with the company’s acquisition by Chiesi Farmaceutici. A stock option covering 17,000 shares of common stock with a per share exercise price of $10.07 was surrendered to the issuer.
Under the merger agreement, a Chiesi subsidiary completed a cash tender offer for all outstanding KalVista common shares at $27.00 per share, after which the subsidiary merged into KalVista on June 11, 2026, making KalVista a wholly owned subsidiary. Per the merger terms, in-the-money options such as this one became fully vested, were cancelled, and converted into the right to receive a cash payment based on the difference between the merger price and the option exercise price, multiplied by the number of option shares. Options with exercise prices at or above $27.00 were cancelled for no consideration.